SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-23-055191
Filing Date
2023-07-06
Accepted
2023-07-06 16:35:03
Documents
5
Group Members
APTA FINANCE SAAPTAFIN S.P.A.ENRICO CAVAZZAFRANCESCA CAVAZZAMARTINA CAVAZZA PRETAPAOLO CAVAZZASILVIA CAVAZZA

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 26 TO SCHEDULE 13D ea181373-13da26esset_regen.htm SC 13D/A 135250
2 JOINT FILING AGREEMENT ea181373ex99-1_regen.htm EX-99.1 12629
3 CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT, DATED AS OF JULY 3, 2023, BY AN ea181373ex99-2_regen.htm EX-99.2 91305
4 CONVERTIBLE PROMISSORY NOTE, DATED JULY 3, 2023 ea181373ex99-3_regen.htm EX-99.3 32423
5 WARRANT, DATED JULY 3, 2023 ea181373ex99-4_regen.htm EX-99.4 64605
  Complete submission text file 0001213900-23-055191.txt   338019
Mailing Address 15245 SHADY GROVE ROAD SUITE 470 ROCKVILLE MD 20850
Business Address 15245 SHADY GROVE ROAD SUITE 470 ROCKVILLE MD 20850 301-208-9191
REGENERX BIOPHARMACEUTICALS INC (Subject) CIK: 0000707511 (see all company filings)

IRS No.: 521253406 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-37889 | Film No.: 231074057
SIC: 2834 Pharmaceutical Preparations

Mailing Address VIA SUDAFRICA 20 ROME L6 00144
Business Address
Essetifin SPA (Filed by) CIK: 0001092601 (see all company filings)

Fiscal Year End: 1231
Type: SC 13D/A